[1].   Wilmoth, J. R., Mizoguchi, N., Oestergaard, M. Z., Say, L., Mathers, C. D., Zureick-Brown, S., Inoue, M., Chou, D., 2012, A New Method for Deriving Global Estimates of Maternal Mortality. Statistics, Politics, and Policy, 3(2), 1.

[2].   Charles, C. E., Ogochukwu, R. E., Chukwunonso, S. E., 2024, Public-Private Partnerships In Health Sector Innovation: Lessons From Around The World. imsrj, 4(4), 484–499.

[3].   Rawlings, C., Adekunle, O. A., Chioma, A. O., Oloruntoba, B., Jeremiah, O. A., 2024, Psychological Resilience in Healthcare Workers: A Review of Strategies and Intervention. World J. Bio. Pharm. Health Sci., 17(2), 387–395.

[4].   Babatunde, S. O., Ekundayo, D., Udeaja, C., Abubakar, U. O., 2022, An investigation into the sustainability practices in PPP infrastructure projects: A case of Nigeria. Smart and Sustainable Built Environment, 11(1), 110–125.

[5].   Salangwa, C., Munthali, R., Mfune, L., Nyirenda, V. K., 2025, Public-Private Partnership (PPP) and Health Service Delivery in Malawi: The Case of Christian Health Association of Malawi (CHAM) Facilities in Mzimba District. Health Policy OPEN, 8: 100139.

[6].   Basu, S., Andrews, J., Kishore, S., Panjabi, R., Stuckler, D., 2012, Comparative Performance of Private and Public Healthcare Systems in Low- and Middle-Income Countries: A Systematic Review. PLoS Med, 9(6), e1001244.

[7].   Whyle, E. B., Olivier, J., 2016, Models of Public–Private Engagement for Health Services Delivery and Financing in Southern Africa: A Systematic Review. Health Policy Plan., 31(10), 1515–1529.

[8].   Batjargal, T., Zhang, M., 2021, Review of Key Challenges in Public-Private Partnership Implementation, J Infrastruct Policy Dev, 5(2), 1378.

[9].   Herman, N. G., Rosenberg, L. R., Moursi, A. M., 2008, Public-private collaboration to improve oral health status of children enrolled in head start in New York City, N Y State Dent J, 74(4), 32.

[10].  Ravindran, T. K. S., 2011, Public-Private Partnerships in Maternal Health Services. Economic and Political Weekly, 46(48), 43–52.

[11].  McKee, M., Edwards, N., Atun, R., et al., 2006, Public–private partnerships for hospitals. Bull World Health Organ, 84:890–6. Cited by Hellowell, M., 2019, Are Public–Private Partnerships the Future of Healthcare Delivery in Sub-Saharan Africa? Lessons from Lesotho. BMJ Glob Health, 4(2), e001217.

[12].  Anyaehie, U., Nwakoby, B., Chikwendu, C., Dim, C., Uguru, N., Oluka, C., Ogugua, C., 2014, Constraints, Challenges and Prospects of Public-Private Partnership in Healthcare Delivery in a Developing Economy. Ann Med Health Sci Res, 4(1), 61.

[13].  Basabih, M., Prasojo, E., Rahayu, A. Y. S., 2022, Hospital Services Under Public-Private Partnerships, Outcomes and Challenges: A literature Review. Journal of Public Health Research, 11(3), 1.

[14].  Sekhri, N., Feachem, R., Ni, A., 2011, Public-Private Integrated Partnerships Demonstrate the Potential to Improve Health Care Access, Quality, And Efficiency. Health Affairs, 30(8), 1498–1507.

[15].  Okafor, C., 2016, Improving Outcomes in the Nigeria Healthcare Sector Through Public- Private Partnership. Afr. Res. Rev., 10(4), 1.

[16].  Van den Heever, A., 2017, Developing Coordinated Public-Private Partnerships and Systems for Financing Health in Africa: Experiences from Africa and India. 2017. WITS-AfDB Publication

[17].  Nigeria, 2006, National Policy on Public-Private Partnership for Health in Nigeria. Abuja [Nigeria], Federal Ministry of Health, 2006.

[18].  Mugo, M. G., 2023, The Impact of Health Insurance Enrollment on Health Outcomes in Kenya. Health Economics Review, 13(1), 42.

[19].  Erlangga, D., Suhrcke, M., Ali, S., Bloor, K., 2019, The Impact of Public Health Insurance on Healthcare Utilization, Financial Protection and Health Status in Low- and Middle-Income Countries: A Systematic Review. PLoS ONE, 14(8), e0219731.

[20].  Ferreira, D. C., Marques, R. C., 2021, Public-Private Partnerships in Health Care Services: Do they Outperform Public Hospitals Regarding Quality and Access? Evidence from Portugal. Socio-Economic Planning Sciences, 73, 100798.

[21].  Public Private Partnership in the Health Sector: Practical Issues for Consideration. World Bank. Accessed: Jun. 09, 2025. [Online]. Available: https://documents.worldbank.org/en/publication/documents-reports/documentdetail/en/526271561755472041.

[22].  Nuhu, S., Mpambije, C. J., Ngussa, K., 2020, Challenges in Health Service Delivery under Public-Private Partnership in Tanzania: Stakeholders’ Views from Dar es Salaam Region. BMC Health Serv Res, 21(1), 765.

[23].  Asasira, J., Ahimbisibwe, F., 2018, Public-Private Partnership in Health Care and Its Impact on Health Outcomes: Evidence from Ruharo Mission Hospital in Uganda. IJSSS, 6(12), 79.

[24].  Nwafor, N. F., Okoye, U. O., 2024, Perceived Inadequate Welfare of Healthcare Professionals in Nigeria and its Influence on Service Delivery and Patients’ Safety. jswds, 6(2), 13–29.

[25].  Bello, S., Oni, T. E., Salawu, M. M., 2021, Job Satisfaction and Psychological Health Among Health Workers in Lagos State Teaching Hospital, Nigeria. Ann Ib Postgrad Med, 19(2), 147–155.

[26].  Gbala, O., Adeniyi, O. O., Olaoye, O., Oke, O. F., Bakare, B., et al., 2024, The Impact of High Electricity Tariffs on the Tertiary Healthcare System in Nigeria: A Critical Review. Int. J. Res. Manage., 6(2), 423–428.

[27].  Eze, O. I., Iseolorunkanmi, A., Adeloye, D., 2024, The National Health Insurance Scheme (NHIS) in Nigeria: Current Issues and Implementation Challenges. Journal of Global Health Economics and Policy, 4.

[28].  Okafor, I. J., 2020, Health Infrastructure and Implementation Of Health Policy In Nigeria: A Case of NHIS In FCT, Abuja. International Journal of Management, Social Sciences, Peace and Conflict Studies, 3(4).

[29].  Omoleke, I. I., Taleat, B. A., 2018, Contemporary Issues and Challenges of Health Sector in Nigeria. Research Journal of Health Sciences, 5(4), 210.

[30].  Rosser, J. I., Aluri, K. Z., Kempinsky, A., Richardson, S., Bendavid, E., 2022, The Effect of Healthcare Worker Density on Maternal Health Service Utilization in Sub-Saharan Africa. The American Journal of Tropical Medicine and Hygiene, 106(3), 939-944.

[31].  Ogundeji, Y. K., Omoleke, S. A., 2015, PPP and the Development of Healthcare Infrastructure: A Review. Journal of Applied Sciences and Environmental Management, 19(3), 469-474.

[32].  Uplekar M., 2016, Public-Private Mix for Tuberculosis Care and Prevention. What Progress? What Prospects? Int J Tuberculosis Lung Disease, 20(11),1424–9.

[1].   Uzochukwu, B. S. C., et al., 2015, "Policy Barriers and Opportunities for Vaccine Production in Nigeria." Journal of Public Health Policy, 36(4), 471-487.

[2].   Nkengasong, J., Ndembi, N., & Moeti, M. 2021, Vaccine Manufacturing in Africa: Addressing the Barriers. The Lancet Global Health, 9(6), e758-e763.

[3].   Addressing the Barriers. The Lancet Global Health, 9(6), e758-e763.

[4].   AFDB (African Development Bank), 2023, Strengthening Africa’s Pharmaceutical and Vaccine Manufacturing Capacity. Retrieved from www.afdb.org

[5].   WHO (World Health Organization), 2021, The mRNA Vaccine Technology Transfer Hub. Retrieved from www.who.int

[6].   Clift, C., 2020, Understanding Technology Transfer in the Vaccine Industry. Vaccine Insights, 11(3), 301-317.

[7].   GAVI (Global Alliance for Vaccines and Immunization), 2023, Vaccine Supply Chain and Manufacturing Strategies. Retrieved from www.gavi.org

[8].   Kraus, M., Smith, D., & Alhassan, T., 2020, Evaluating Technology Transfer in African Vaccine Manufacturing. Journal of Global Health Policy, 32(2), 112-129.

[9].   AfDB (African Development Bank), 2023, Strengthening Africa’s Pharmaceutical and Vaccine Manufacturing Capacity. Retrieved from www.afdb.org

[10].  Okereke, E., & Ekeke, P., 2021, Policy Frameworks for Sustainable Vaccine Manufacturing in Nigeria. Journal of African Health Economics, 27(1), 45-62.

[11].  Chakraborty, T., & Singh, R., 2020, The Role of Technology Transfer in Vaccine Production: Lessons from India. International Journal of Vaccine Research, 18(4), 189-203.

[12].  World Health Organization (WHO), 2021, Local production and technology transfer to increase access to COVID-19 vaccines: Policy brief. https://www.who.int/publications/i/item/WHO-UHL-PHC-SPP-2021.01

[13].  Narayan, V., & Campbell, S., 2019, Healthcare Investments in Emerging Markets: The Role of Collaborative Agreements. Healthcare Finance Journal, 24(2), 195-210.

[14].  World Health Organization, 2021, Global Vaccine Manufacturing and Regulatory Frameworks. WHO Press.

[15].  Marston, N., & Morgan, G., 2020, "Capacity Constraints in Developing Countries' Health Sectors: A Study on Vaccine Production." Development Journal, 30(1), 113-130.

[16].  Rogers, E. M., 2003, Diffusion of Innovations (5th ed.). Free Press.

[17].  Kraus, M., Smith, D., & Alhassan, T., 2020, Evaluating Technology Transfer in African Vaccine Manufacturing. Journal of Global Health Policy, 32(2), 112-129.

[18].  Gavi, the Vaccine Alliance. 2022, Sustainable vaccine manufacturing in Africa: Gavi’s position paper. https://www.gavi.org

[19].  World Health Organization (WHO), 2023, Global Vaccine Market Report: Nigeria’s Standing in Local Production. WHO Publications.

[20].  Nigerian Ministry of Health, 2022, Policy Review on Nigeria’s Vaccine Production Capacity. Federal Ministry of Health Report.

[21].  GAVI, 2023, Nigeria Vaccine Investment Strategy: Funding and Developmental Progress. GAVI Reports on Vaccine Sustainability.

[22].  Chakrabarti, A., Banerjee, S., & Dey, S., 2022, "Growth of the Indian Vaccine Industry: Government Support and Market Expansion." Journal of Vaccine Research and Development, 15(2), 89-105.

[1].   World Health Organization., 2019, World report on vision. https://www.who.int/publications-detail/world-report-on-vision

[2].   Jackson, M. L., Burr, J., & Fielder, A., 2020, Vision, independence and aging: A review of global challenges. Journal of Vision Health, 12(3), 198–210.

[3].   Bitner, R., Chang, L., & Hart, S., 2023, Understanding visual impairment: Causes, classifications, and rehabilitation. Journal of Ophthalmic Research, 45(2), 112–124.

[4].   Pascolini, D., & Mariotti, S. P., 2012, Global estimates of visual impairment: 2010. British Journal of Ophthalmology, 96(5), 614–618. https://doi.org/10.1136/bjophthalmol-2011-300539

[5].   Bourne, R. R. A., Flaxman, S. R., Braithwaite, T., Cicinelli, M. V., Das, A., Jonas, J. B., ... & Resnikoff, S., 2021, Magnitude, temporal trends, and projections of the global burden of uncorrected presbyopia: A systematic review and meta-analysis. The Lancet Global Health, 9(2), e160-e168. https://doi.org/10.1016/S2214-109X(20)30313-2

[6].   Resnikoff, S., Lansingh, V. C., Washburn, L., Felch, W. C., Gauthier, T. M., & Taylor, H. R., 2020, Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): Will we meet the needs? British Journal of Ophthalmology, 104(4), 588–592. https://doi.org/10.1136/bjophthalmol-2019-314336

[7].   Lamoureux, E. L., Hassell, J. B., & Keeffe, J. E., 2009, The determinants of participation in activities of daily living in people with impaired vision. American Journal of Ophthalmology, 147(2), 266–273.e1. https://doi.org/10.1016/j.ajo.2008.08.014

[8].   Tanui, D., 2015, Disability and exclusion: Experiences of people with visual impairments in Kenya. African Journal of Disability, 4(1), 1–8. https://doi.org/10.4102/ajod.v4i1.161

[9].   Nshimiyimana, A., Kalisa, R., & Musabyimana, A., 2022, Barriers to inclusive eye care services in sub-Saharan Africa. African Vision and Health Journal, 6(1), 35–44.

[10].  Finger, R. P., Fenwick, E., Marella, M., & Lamoureux, E. L., 2011, The impact of vision impairment on vision-specific quality of life in Germany. Investigative Ophthalmology & Visual Science, 52(6), 3613–3619. https://doi.org/10.1167/iovs.10-6665

[11].  Gaspar, T., Ferreira, M., Marques, A., Leal, I., & Paiva, T., 2017, Health-related quality of life in children and adolescents: Perceptions of parents and children. Journal of Pediatric Psychology, 42(2), 162–171. https://doi.org/10.1093/jpepsy/jsw060

[12].  Inkeles, A., 2022, Defining quality of life across cultures. Social Indicators Research, 160(1), 5–22.

[13].  World Health Organization., 1997, WHOQOL: Measuring quality of life. https://www.who.int/tools/whoqol

[14].  Jones, L., Mohandas, T., & Tadi, P., 2019, Visual impairment and its impact on mental health. Community Eye Health Journal, 32(105), 26–30.

[15].  Rees, G., Fenwick, E. K., & Keeffe, J. E., 2010, Impact of age-related macular degeneration on quality of life. British Journal of Ophthalmology, 94(5), 632–636. https://doi.org/10.1136/bjo.2009.164970

[16].  Evans, J. R., Fletcher, A. E., & Wormald, R. P. L., 2007, Depression and anxiety in visually impaired older people. Ophthalmology, 114(2), 283–288. https://doi.org/10.1016/j.ophtha.2006.10.006

[17].  Yeshanew, B., Abebe, S., & Teshome, D., 2023, Psychosocial outcomes among people with visual impairment in Ethiopia. East African Journal of Health and Social Sciences, 5(2), 115–123.

[18].  Alma, M. A., Van der Mei, S. F., Melis-Dankers, B. J. M., Van Tilburg, T. G., Groothoff, J. W., & Suurmeijer, T. P. B. M., 2011, Participation of the elderly after vision loss. Disability and Rehabilitation, 33(1), 63–72. https://doi.org/10.3109/09638288.2010.488708

[19].  Riazi, A., Rowe, F. J., & Peat, N., 2020, The impact of visual impairment on psychosocial outcomes in adults: A systematic review. Health & Social Care in the Community, 28(6), 2020–2034. https://doi.org/10.1111/hsc.13013

[20].  Kuper, H., Polack, S., & Eusebio, C., 2008, A review of the literature on barriers to the uptake of eye care services in developing countries. Ophthalmic Epidemiology, 15(2), 73–82. https://doi.org/10.1080/09286580701877840

[21].  Gupta, J., & Vegelin, C., 2016, Sustainable development goals and inclusive development. International Environmental Agreements: Politics, Law and Economics, 16(3), 433–448. https://doi.org/10.1007/s10784-016-9323-z

[22].  Reddy, S., 2016, Inclusion of disability in global development: SDGs and beyond. International Journal of Disability Studies, 10(1), 7–14.

[23].  International Agency for the Prevention of Blindness (IAPB)., 2022, 2030 in sight: Strategy for ending avoidable sight loss. https://www.iapb.org

[24].  Khadka, J., McAlinden, C., & Pesudovs, K., 2010, Quality assessment of vision-related quality of life questionnaires. Optometry and Vision Science, 87(12), 1029–1040. https://doi.org/10.1097/OPX.0b013e3181f1f39d

[25].  Mangione, C. M., Lee, P. P., Pitts, J., Gutierrez, P., Berry, S., & Hays, R. D., 2001, Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology, 119(7), 1050–1058. https://doi.org/10.1001/archopht.119.7.1050

[26].  Post M. W., 2014, Definitions of quality of life: what has happened and how to move on. Topics in spinal cord injury rehabilitation, 20(3), 167–180. https://doi.org/10.1310/sci2003-167

[27].  Barry, R. J., De Kock, T. P., Mathews, D. E., & Lingham, G., 2017, Limitations of vision‑specific quality‑of‑life instruments. Clinical Vision Journal, 12(3), 145–152.

[28].  Béchetoille, A., Arnould, B., Bron, A., Baudouin, C., Renard, J.-P., Sellem, E., … Rouland, J.-F., 2008, Measurement of health-related quality of life with glaucoma: Validation of the Glau‑QoL 36‑item questionnaire. Acta Ophthalmologica, 86(1), 71–80. https://doi.org/10.1111/j.1600-0420.2007.00999.x

[29].  Hays R. D., Hahn H., & Marshall G., 2002, Use of the SF‑36 and other health‑related quality of life measures to assess persons with disabilities. Archives of Physical Medicine and Rehabilitation, 83(S4), S4–S9.

[30].  Juniper, E. F., Guyatt, G. H., & Jaeschke, R., 1996, How to develop and validate a new health-related quality of life instrument. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (2nd ed., pp. 49–56). Lippincott‑Raven Publishers.

[31].  Lee, B. L., Suh, W., Kim, T. H., Park, J. W., Kim, J. H., & Kim, D. J., 2005, Assessing quality of life in individuals with visual impairment. Health and Quality of Life Outcomes, 3, 21.

[32].  Pesudovs, K., Garamendi, E., & Elliott, D. B., 2006, A quality of life comparison of people wearing spectacles, contact lenses, or having undergone refractive surgery. Journal of Refractive Surgery, 22(1), 19–27. https://doi.org/10.3928/1081-597X-20060101-07

[33].  Margolis, M. K., Coyne, K., Kennedy‑Martin, T., Baker, T., Schein, O., & Revicki, D. A., 2002, Vision-specific instruments for the assessment of health-related quality of life and visual functioning: A literature review. Pharmacoeconomics, 20(12), 791–812. https://doi.org/10.2165/00019053‑200220120‑00001

[34].  Terwee, C. B., Bot, S. D. M., de Boer, M. R., van der Windt, D. A. W. M., Knol, D. L., Dekker, J., Bouter, L. M., & de Vet, H. C. W., 2007, Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology, 60(1), 34–42. https://doi.org/10.1016/j.jclinepi.2006.03.012

[35].  Marans, R. W., 2003, Understanding environmental quality through quality of life studies: the 2001 DAS and its use of subjective and objective indicators. Journal of Landscape and Urban Planning, 65(1–2), 73–83.

[36].  Šemrov, A., Tadić, V., Cortina-Borja, M., Rahi, J. S., & Resilience and Childhood Visual Impairment Study Group, 2023, Individual, family, and environmental determinants of vision-related quality of life of children and young people with visual impairment. PloS one, 18(11), e0294532. https://doi.org/10.1371/journal.pone.0294532

[37].  Frost, M. H., Reeve, B. B., Liepa, A. M., Stauffer, J. W., & Hays, R. D., 2007, What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value in Health, 10(Suppl 2), S94–S105.

[38].  Purola, P., Taipale, V., & Raitanen, J., 2021, Impact of vision on generic health‐related quality of life – A systematic review. Acta Ophthalmologica, 101(3), 229-238. https://doi.org/10.1111/aos.15676

[39].  Vu, H. T., Keeffe, J. E., McCarty, C. A., & Taylor, H. R., 2005, Impact of unilateral and bilateral vision loss on quality of life. The British journal of ophthalmology, 89(3), 360–363. https://doi.org/10.1136/bjo.2004.047498

[40].  Chia, E. M., Wang, J. J., Rochtchina, E., Smith, W., Cumming, R. R., & Mitchell, P., 2004, Impact of bilateral visual impairment on health-related quality of life: The Blue Mountains Eye Study. Investigative Ophthalmology & Visual Science, 45(1), 71–76. https://doi.org/10.1167/iovs.03-0661

[1].   World Health Organization (WHO), 2024, WHO coronavirus (COVID-19) dashboard. Retrieved from https://covid19.who.int

[2].   Dhama, K., et al., 2020, COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics, 16(6), 1232–1238.

[3].   Apanga, P. A., et al., 2020, COVID-19 in Ghana: A call for urgent public health interventions. Journal of Public Health in Africa, 11(2), 180–184.

[4].   Soeters, H. M., et al., 2022, Herd immunity and COVID-19 vaccination: Global targets and challenges. The Lancet Infectious Diseases, 22(6), e174–e183.

[5].   Kwon, H., & Rahmati, M., 2022, Global disparities in COVID-19 vaccine access. The Lancet Global Health, 10(5), e728–e729.

[6].   Ghana Health Service (GHS), 2023, Annual COVID-19 Vaccination Coverage Report. Accra: GHS.

[7].   Effiong, A., et al., 2023, COVID-19 vaccine awareness and hesitancy among Nigerian undergraduate students. Journal of Community Health, 48(4), 827–838.

[8].   Kreps S. E., Kriner D. L., 2021, Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment. Vaccine, 39:3250–8. https://doi.org/10.1016/j.vaccine.2021.04.044

[9].   Adiyoso, W., et al., 2023, Health Belief Model and COVID-19 vaccine hesitancy: A cross-sectional study. Journal of Public Health Research, 12(3), 245–257.

[10].  Khairat, S., et al., 2022, Factors affecting COVID-19 vaccine uptake in low- and middle-income countries. BMC Public Health, 22, 1230.

[11].  Janz, N. K., & Becker, M. H. 1984, The Health Belief Model: A decade later. Health Education Quarterly, 11(1), 1–47.

[12].  Glanz, K., Rimer, B. K., & Viswanath, K., (Eds.). 2015, Health Behavior: Theory, Research, and Practice (5th ed.). San Francisco, CA: Jossey-Bass (Wiley).

[13].  Alhassan, R. K., et al., 2021, COVID-19 vaccine hesitancy in Ghana: Experiences from the field. PLOS ONE, 16(11), e0261315. https://doi.org/10.xxxx

[14].  Leonardelli, I., et al., 2023, Applying the Health Belief Model to vaccine intention among adolescents. Vaccine, 41(2), 295–302.

[15].  Ghana Statistical Service (GSS), 2021, population and housing census. Accra: Ghana Statistical Service.

[16].  Ahmed, M., 2016, Determining sample size for research activities. Educational and Psychological Measurement, 30(3), 607–610.

[17].  Lamuda, P., et al., 2020, Age differences in COVID-19 vaccine hesitancy: A global perspective. Journal of Health Psychology, 25(6), 789–801.

[18].  Kengadaran, S., & Anusha, P., 2023, Awareness and attitudes towards COVID-19 vaccination in Tamil Nadu. Indian Journal of Public Health Research & Development, 14(3), 210–215.

[19].  Naidoo, R., et al., 2023, Cultural factors and vaccine uptake: Lessons from the COVID-19 pandemic. Social Science & Medicine, 317, 115571.

[20].  Alshagrawi, M. 2024, Predictors of COVID-19 vaccine uptake using the Health Belief Model. Journal of Public Health Research, 13(2), 245–257.

[21].  Abubakari, A., et al., 2023, Determinants of COVID-19 vaccine readiness and hesitancy among adults in Sub-Saharan Africa. BMC Public Health, 23(1), 112. https://doi.org/10.xxxx

[22].  Kuatewo, K., et al., 2025, Sources of COVID-19 vaccine misinformation and their impact on uptake in Ghana. Vaccine, 43(2), 221–229.

[23].  Rotenberg, S., et al., 2021, Accessibility of COVID-19 vaccination for people with disabilities. Disability and Health Journal, 14(4), 101117.

[24].  Roberts, R., et al., 2022, Interpersonal influences on COVID-19 vaccination decisions. Health Promotion International, 37(6), daac053.

[25].  Limbu, Y. B., et al., 2022, Gender differences in COVID-19 vaccine hesitancy: Insights from the Health Belief Model. Preventive Medicine, 158, 107014.

[26].  Odikro, A., et al., 2020, Strategies to improve COVID-19 vaccine acceptance in Ghana. African Journal of Health Sciences, 33(5), 1–10.

[1].   Gobena, T., Enyew, D. B., Kenay, A., & Wondirad, Y., 2024, Onsite training-mentoring intervention improves data quality: an implementation research. BMC Public Health, 24(1), 3110.

[2].   Nambiar, B., Hargreaves, D. S., Morroni, C., Heys, M., Crowe, S., Pagel, C., & Colbourn, T., 2016, Improving health-care quality in resource-poor settings. Bulletin of the World Health Organization, 95(1), 76.

[3].   Gobena, T., Enyew, D. B., Kenay, A., & Wondirad, Y., 2024, Onsite training-mentoring intervention improves data quality: an implementation research. BMC Public Health, 24(1), 3110.

[4].   Federal Ministry of Health (FMoH).  2025, Revised Policy on NHMIS. Abuja:FMoH.

[5].   Nutley, T., & Reynolds, H., 2013, Improving the use of health data for health system strengthening. Global health action, 6(1), 20001.

[6].   Uba, B. V., Waziri, N. E., Adegoke, O. J., Akerele, A., Gidado, S., Usifoh, N., & Nguku, P., 2021, Pilot implementation of a routine immunization module of the district health information system version 2 in Kano State, Nigeria, 2014-2015. The Pan African Medical Journal, 40(Suppl 1), 5.

[7].   Mboera, L. E., Rumisha, S. F., Mbata, D., Mremi, I. R., Lyimo, E. P., & Joachim, C., 2021, Data utilisation and factors influencing the performance of the health management information system in Tanzania. BMC Health Services Research, 21(1), 498.

[8].   Chaulagai, C. N., Moyo, C. M., Koot, J., Moyo, H. B., Sambakunsi, T. C., Khunga, F. M., & Naphini, P. D., 2005, Design and implementation of a health management information system in Malawi: issues, innovations and results. Health policy and planning, 20(6), 375-384.

[9].   Alemie, H. K., 2024, Assessing the Relevance of African-based Institutions in Becoming WHO Collaborating Centres in Digital Health (Doctoral dissertation, Hochschule für Angewandte Wissenschaften Hamburg).

[10].  Meekers, D., Olutola, O., & Turk, L. A., 2023, Using responsive feedback from routine monitoring data to guide course corrections for a family planning intervention in Nigeria. Gates Open Research, 7, 75.

[11].  Kawakyu, N., Coe, M., Wagenaar, B. H., Sherr, K., & Gimbel, S., 2023, Refining the Performance of Routine Information System Management (PRISM) framework for data use at the local level: An integrative review. PLoS One, 18(6), e0287635.

[12].  Wilms, M. C., Mbembela, O., Prytherch, H., Hellmold, P., & Kuelker, R., 2014, An in-depth, exploratory assessment of the implementation of the National Health Information System at a district level hospital in Tanzania. BMC health services research, 14(1), 91.

[13].  Glèlè Ahanhanzo, Y., Ouendo, E. M., Kpozèhouen, A., Levêque, A., Makoutodé, M., & Dramaix-Wilmet, M., 2014, July 24. Data quality assessment in the routine health information system: an application of the Lot Quality Assurance Sampling in Benin. Health Policy and Planning, 30(7), 837–843. https://doi.org/10.1093/heapol/czu067.

[14].  Yourkavitch, J., Prosnitz, D., & Herrera, S., 2019, Data quality assessments stimulate improvements to health management information systems: evidence from five African countries. Journal of Global Health, 9(1). https://doi.org/10.7189/jogh.09.010806.

[15].  Oladoyin, V., Adedini, S., Ijadunola, K., Ogunwemimo, H., Folorunso, O., Chukwu, E., Okoli, U., Adoghe, A., Oyeniyi, S., Adetiloye, O., & Fatusi, A., 2025, The assessment of routine health information system performance towards improvement of quality of reproductive, maternal, newborn, child and adolescent health services in Ondo and Ekiti States, Nigeria. PLoS ONE, 20(1), e0318010. https://doi.org/10.1371/journal.pone.0318010

[16].  Mambo, S. N., Odhiambo-Otieno, G. W., Ochieng’-Otieno, G., & Mwaura-Tenambergen, W., 2021, Health systems strengthening: assessing the influence of organizational factors of community health volunteers on use of community based health information systems in selected counties, Kenya. International Journal of Community Medicine and Public Health, 8(6), 2724. https://doi.org/10.18203/2394-6040.ijcmph20211975

[17].  Adefolarin, A. O., Gershim, A., Sola, A. O., & Oye, G., 2021, The effect of training and supervision on primary health care workers’ competence to deliver maternal depression inclusive health education in Ibadan, Nigeria: a quasi-experimental study. BMC Health Services Research, 21(1). https://doi.org/10.1186/s12913-021-07208-3

[18].  Gergen, J., Josephson, E., Coe, M., Ski, S., Madhavan, S., & Bauhoff, S., 2017, Quality of Care in Performance-Based Financing: How It Is Incorporated in 32 Programs Across 28 Countries. Global Health: Science and Practice, 5(1), 90–107. https://doi.org/10.9745/ghsp-d-16-00239

[19].  Zodpey, S., & Negandhi, H., 2016, Improving the quality and use of routine health data for decision-making. Indian Journal of Public Health, 60(1), 1. https://doi.org/10.4103/0019-557x.177248

[20].  Musoke, D., Ndejjo, R., Atusingwize, E., Mukama, T., Ssemugabo, C., & Gibson, L., 2019, Performance of community health workers and associated factors in a rural community in Wakiso district, Uganda. African Health Sciences, 19(3), 2784–2797. https://doi.org/10.4314/ahs.v19i3.55

[21].  Console, M., & Lenzerini, M., 2023, Editorial: Special Issue on Quality Aspects of Data Preparation. Journal of Data and Information Quality, 15(4), 1–2. https://doi.org/10.1145/3626461

[22].  Ihekweazu, C., Ossai, P., Nnaji, R., Osigwe, U., & Ngozi, M., 2019, Interoperability of Surveillance Data Collection Tools (District Health Information System 2 and District Vaccine Data Management Tools) in Enugu State, Nigeria, From 2015-2018. Iproceedings, 5(1), e15235. https://doi.org/10.2196/15235

[23].  Semo, B. W., 2014, Improving the quality of health information: a qualitative assessment of data management and reporting systems in Botswana. Health Research Policy and Systems, 12(1). https://doi.org/10.1186/1478-4505-12-7

[24].  Tang, X. Y., Yan, X. X., Wei, X., Qin, Q. L., Lin, Y. D., Geater, A., Deng, Q. Y., Zhong, G., & Li, Q., 2021, Timeliness, completeness, and timeliness-and-completeness of serial routine vaccinations among rural children in Southwest China: A multi-stage stratified cluster sampling survey. Vaccine, 39(24), 3236–3249. https://doi.org/10.1016/j.vaccine.2021.04.048

[25].  Jeilani, A., & Hussein, A., 2025, Impact of digital health technologies adoption on healthcare workers’ performance and workload: perspective with DOI and TOE models. BMC Health Services Research, 25(1). https://doi.org/10.1186/s12913-025-12414-4

[26].  Ogbuabor, D., Ghasi, N., Nwangwu, C., Okenwa, U., Ezenwaka, U., & Onwujekwe, O., 2023, Evaluating an Intervention to Improve the Quality of Routine Immunization Data and Monitoring System in Enugu State, Nigeria: A Pre-and Post-Study. Nigerian Journal of Clinical Practice, 26(Suppl 1), S103-S112.

[1].   U.S. Food and Drug Administration (FDA), 2013, Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. CDER.

[2].   European Medicines Agency (EMA), 2010, Guideline on the Investigation of Bioequivalence. EMA/CHMP/EWP/1401/98 Rev 1/Corr*.

[3].   Indian Council of Medical Research (ICMR), 2017, Ethical Guidelines for Biomedical and Health Research Involving Human Participants. New Delhi: ICMR.

[4].   International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2016, Guideline for Good Clinical Practice E6(R2). ICH Harmonized Tripartite Guideline.

[5].   DeFronzo, R. A., Goodman, A. M., 1995, Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med., 333(9):541–549.

[6].   Vedtofte, L., Knop, F. K., Vilsbøll, T., 2017, Efficacy and safety of linagliptin for the treatment of type 2 diabetes. Expert Opin Pharmacother., 18(9):859–865.

[7].   Nauck, M. A., Vilsbøll, T., Gallwitz, B., et al., 2009, Incretin-based therapies: viewpoint on the way to consensus. Diabetes Care., 32(Suppl 2):S223–S231.

[8].   Zhang, L., He, L., Gong, L., et al., 2021, Diabetes mellitus and the risk of cardiovascular events and death: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord., 21(1):1–11.

[9].   Peters, N. H. G. M., De Smet, P. A. G. M., van der Worp, H. B., et al., 2021, Bioequivalence and generic drugs: a European perspective. Eur J Clin Pharmacol., 77:1769–1776.

[10].  Kamal, M. A., Alexiou, A., Zaman, G. S., 2015, Bioequivalence assessment: A review on its importance in generic product development. Int J Pharma Sci Res., 6(8):788–793.

[11].  Scordo, M. G., Aklillu, E., Yasar, Ü., et al., 2020, Bioequivalence studies: regulatory aspects and global trends. Eur J Clin Pharmacol., 76:151–160.

[12].  Owusu Obeng, A., Hamada, Y., Ebieyan, S., et al., 2019, Bioanalytical method validation in pharmacokinetic studies: regulatory framework and scientific challenges. J Pharm Biomed Anal., 170:630–638.

[13].  Bailey, C. J., Turner, R. C., 1996, Metformin. N Engl J Med., 334:574–579.

[14].  Battelino, T., et al., 2015, Clinical efficacy and safety of linagliptin and metformin in type 2 diabetes: a review. Adv Ther., 32(7):599–618.

[15].  Holstein, A., Plaschke, A., Egberts, E. H., 2017, Lower incidence of hypoglycemia with DPP-4 inhibitors. Diabetes Obes Metab., 19(7):950–957.

[16].  Wienen, W., Diefenbach, K., Bader, G., et al., 2010, Linagliptin, a xanthine-based DPP-4 inhibitor. Biochem Pharmacol., 80(6):861–870.

[17].  Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al., 2015, Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care., 38(1):140–149.

[18].  Chaturvedi, N., Matthews, D. R., et al., 2018, Study designs for generic fixed-dose combination formulations: regulatory expectations. Int J Clin Pharmacol Ther., 56(11):518–535.

[19].  U.S. Food and Drug Administration (FDA), 2001, Statistical Approaches to Establishing Bioequivalence. CDER.

[20].  Swanson, J., et al., 2020, Generic substitution and therapeutic equivalence in diabetes management. Drug Healthc Patient Saf., 12:103–112.

[21].  Remuzzi, G., Schieppati, A., 2019, Guidelines for drug bioequivalence and bioavailability studies. Br J Clin Pharmacol., 85(3):424–432.

[22].  World Medical Association, 2013, Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. JAMA., 310(20):2191–2194.

[23].  EMA, 2010, Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples. EMA/INS/GCP/532137/2010.

[24].  EMA, 2009, Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009.

[25].  Chae, Y. S., et al., 2021, An overview of bioequivalence study designs and regulatory approaches worldwide. Ther Innov Regul Sci., 55:1328–1343.